Prevalence and Characteristics of Polyneuropathy in Atypical Parkinsonian Syndromes: An Explorative Study

(1) Background: Peripheral nerve involvement is increasingly recognized in Parkinson’s disease (PD). Although non-motor symptoms and postural instability are early features of atypical parkinsonian syndromes (APS), peripheral neuropathies in APS have not been addressed in detail thus far. Therefore, the aim of this study was to investigate the prevalence and characteristics of polyneuropathies (PNP) in multiple system atrophy (MSA) and progressive supranuclear palsy (PSP), as representative syndromes of APS. (2) Methods: In total, 8 MSA and 6 PSP patients were comprehensively analyzed regarding subjective, clinical (motor and non-motor) and paraclinical PNP features using nerve conduction studies and high resolution nerve ultrasounds (HRUS). (3) Results: A total of 87.5% of MSA and 66.7% of PSP patients complained of at least one neuropathic symptom, with electrophysiological confirmation of PNP in 50.0% of both, MSA and PSP patients. PNP symptom severity in PSP and motor nerve amplitude in MSA were associated with compromised motor function. Morphologic nerve examination by HRUS showed few alterations according to the axonal type of PNP. (4) Conclusions: The overall high PNP symptom burden may be partially credited to the significant prevalence of electrophysiologically diagnosed PNP, and impact motor aspects of APS. The findings of this exploratory study reinforce further investigations on a larger scale, in order to elucidate peripheral nerve involvement and the underlying pathophysiological mechanisms of APS.

Experience in using nucleotides for the management Of patients with diabetic polyneuropatie

Diabetic polyneuropathy (DPN) is one of the most common complications of diabetes mellitus. Management of patients with DPN is a complex medical and socioeconomic problem. The article presents the observational study results of 40 patients with type 2 diabetes mellitus complicated by DPN. Patients of the treatment group received Keltikan® complex in combination with basic therapy for 60 days, patients of the control group received only basic therapy. The treatment resulted in the positive changes observed in both groups, while the group taking Keltikan® complex showed more pronounced changes according to the total neurological symptoms (TSS) scale, the neuropathic dysfunctional score (NDS) scale, the neuropathic symptom score (NSS) scale, and also according to the electroneuromyography results.